siRNA Allele Selectivity for CLCN7 Mutation Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current siRNAs struggle to selectively silence the mutated allele of the CLCN7 gene responsible for CLCN7-dependent ADO2, with challenges in discriminating between mutated and wild-type alleles, leading to inadequate therapeutic efficacy.
Innovation Solution
Designing novel siRNAs that are complementary to the region comprising a point mutation in the CLCN7 mRNA, with specific sequences and nucleotide mismatches to enhance selectivity and efficacy, allowing for selective reduction of the mutated CIC-7 protein expression while sparing the wild-type protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If siRNA sequences are designed to be complementary to the mutated allele of CLCN7 mRNA, then the selectivity for mutated allele is improved, but the ability to discriminate between mutated and wild-type alleles deteriorates
Solution Approach 1:
The patent applies local quality by designing siRNA sequences with specific nucleotide mismatches at particular positions relative to the mutation site. The mismatch position and type are carefully selected to create differential binding affinity: the siRNA binds strongly to the mutated allele while binding weakly to the wild-type allele. This local modification of sequence complementarity allows the same siRNA to selectively silence the mutated gene without affecting the wild-type gene, resolving the contradiction between selectivity and discrimination ability.
2Productivity
If siRNA sequences are made completely complementary to the target mRNA, then the silencing efficacy is improved, but the selectivity between mutated and wild-type alleles deteriorates
Solution Approach 1:
The patent changes the parameters of siRNA sequence composition by introducing controlled nucleotide mismatches at specific positions. Instead of complete complementarity, the siRNA sequences are designed with 1-3 mismatches strategically positioned relative to the mutation site. This parameter modification creates a threshold effect where the siRNA maintains sufficient binding affinity to silence the mutated allele (achieving up to 95% silencing efficacy) while the mismatch prevents effective binding to the wild-type allele, thereby achieving both high efficacy and high selectivity simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized siRNAs achieve up to 95% reduction of mutated transcript levels, restoring osteoclast function and alleviating disease symptoms, with no significant impact on wild-type mRNA expression, and are effectively internalized by osteoclastic cells without the need for transfection agents.
Implementation Method 1
siRNAs have the ability to reduce gene expression in an extremely specific way. These are small sequences of double-strand RNA, normally used in laboratory to modify cell function
Implementation Method 2
siRNAs (small interfering RNA) are small RNA sequences complementary to specific sequences of messenger RNA (mRNA), inducing its degradation
Data Source
AI summary
The present invention lies in the field of molecules known as “small interfering RNA” with therapeutic applications. siRNAs have the ability to reduce gene expression in an extremely specific way (1). These are small sequences of double-strand RNA, normally used in laboratory to modify cell function, which revolutionized cell biology by allowing previously precluded molecular manipulations.